Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24d41624f4c12622605b7048517fe8f7 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 |
filingDate |
2010-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2014-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad8486a1d3d12dad46e53f041d5656b0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ff482bd1353861f39b3d1a5a109464f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c237cbc257588b09170f5840602e99b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8d7482f169edc6799024ed9bc61b95b |
publicationDate |
2014-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2010298480-B2 |
titleOfInvention |
Injectable aqueous ophthalmic composition and method of use therefor |
abstract |
The present invention is directed to the provision of an ophthalmic composition suitable for intravitreal injection. The composition includes an amount of complexing agent that reacts with one or more endogenous components (e.g., hyaluronic acid) in the eye to form a mass of enhanced viscosity. This mass can aid in creating a desirable release profile of therapeutic agent. |
priorityDate |
2009-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |